Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.33 |
| ▸ | FABP7 | O15540 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21553193 | 0.83 | PPARG (0.46) | PPARGPPARAHTR2AKMT2APOLB | |
| SCHEMBL20072350 | 0.82 | HTR2A (0.41) | PPARGPPARAHTR2AKMT2APOLB | |
| SCHEMBL5932825 | 0.77 | KMT2A (0.43) | PPARGPPARAHTR2AKMT2APOLB | |
| SCHEMBL20072237 | 0.76 | POLB (0.51) | PPARGPPARAHTR2AKMT2APOLB | |
| SCHEMBL5933473 | 0.73 | PPARG (0.46) | PPARGPPARAHTR2AKMT2APOLB | |
| SCHEMBL5933468 | 0.73 | KMT2A (0.43) | PPARGPPARAHTR2AKMT2APOLB | |
| SCHEMBL23786542 | 0.73 | KMT2A (0.47) | PPARGPPARAHTR2AKMT2APOLB | |
| SCHEMBL4056199 | 0.72 | PPARG (0.42) | PPARGPPARAHTR2AKMT2APOLB | |
| SCHEMBL5932833 | 0.72 | PPARG (0.42) | PPARGPPARAHTR2AKMT2APOLB | |
| SCHEMBL9328050 | 0.72 | KMT2A (0.46) | PPARGPPARAHTR2AKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319540-B2 | HIF 1-alpha antisense oligonucleotides | OLIPASS CORPORATION (KR) | 2022-05-03 | — | — | US | disclosed |
| US-20210292767-A1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319540-B2 | HIF 1-alpha antisense oligonucleotides | HIF1A, HIF1AN, UPF1 | PPARG 1040/4885PPARA 800/4885HTR2A 3918/4885 |
| US-20210292767-A1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | HIF1A, HIF1AN, UPF1 | PPARG 1040/4885PPARA 800/4885HTR2A 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.